Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Recent Tech Transfer Deals (09/2008)

This article was originally published in Start Up

Executive Summary

Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.

You may also be interested in...



AstraZeneca Inks Pact With EU For Coronavirus Vaccine

The agreement will give all EU member states the option to access the drug major's investigational COVID-19 vaccine dubbed AZD1222 "in an equitable manner at no profit during the pandemic."

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Indoco Profits Triple In First Quarter

Indoco has tripled its operating profit in its financial first quarter ended 30 June 2020. The company has also received FDA approval for its generic version of Eli Lilly’s Zyprexa.

Related Companies

UsernamePublicRestriction

Register

LL1131561

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel